Skip to main content
main-content

Medication

Adverse effects

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

11-28-2018 | SGLT2 inhibitors | Commentary | Article

What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

11-28-2018 | SGLT2 inhibitors | At a glance | Article

Real-world studies of SGLT2 inhibition and amputation risk

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

11-14-2018 | SGLT2 inhibitors | News

Registry study supports SGLT2 inhibitor amputation risk

A registry study in The BMJ finds a small but significant increased risk for amputations in patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors.

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

09-12-2018 | SGLT2 inhibitors | Article

Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study

Dave CV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13531

09-05-2018 | Diagnosis | Case study | Article

Acute illness while on a SGLT2 inhibitor and ketogenic diet

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

08-09-2018 | Medications | News

Sex, BMI influence response to common second-line diabetes medications

Researchers have used data from clinical practice and randomized trials to identify simple predictors of patient response to sulfonylureas and thiazolidinediones.

07-26-2018 | Semaglutide | News

Semaglutide tops liraglutide for glycemic control in phase II trial

Patients with type 2 diabetes who are treated with semaglutide experience greater improvements in glycemic control than those given liraglutide, but at the cost of a higher risk for gastrointestinal adverse events, researchers report.

07-23-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

07-16-2018 | Quality of life | Editorial | Article

Tackling clinical inertia: The role of patient engagement

Carmen Soto and David Strain provide their insights on clinical inertia in diabetes care and present the co-production model of open communication as an innovative means to address this widespread clinical issue.

07-04-2018 | Metformin | Highlight | News

First trimester metformin exposure unlikely to raise congenital anomaly risk

A European-wide case–control study finds little evidence for risk to the developing fetus if a mother is taking metformin.

06-29-2018 | Canagliflozin | Highlight | News

OBSERVE-4D: Canagliflozin amputation risk not replicated in real-world data

A study of patients from US administrative claims databases finds no evidence that use of canagliflozin increases the risk for below the knee amputation when compared with other sodium-glucose cotransporter 2 inhibitors or with other antidiabetic medications.

06-27-2018 | Sotagliflozin | ADA 2018 | News

SGLT2 inhibitor benefits in type 1 diabetes persist over longer term

The DEPICT-1 and inTandem1 investigators have released their 52-week findings, revealing persistent reductions in glycated hemoglobin with SGLT2 inhibition, but a slightly increased risk for diabetic ketoacidosis.

05-18-2018 | Type 2 diabetes | Review | Article

Combination glucose-lowering therapy plans in T2DM: Case-based considerations

Blonde L, Dipp S, Cadena D. Adv Ther 2018. doi: 10.1007/s12325-018-0694-0

03-28-2018 | Cardiovascular disorders | Article

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death, and safety outcomes in type 2 diabetes: A systematic review

Rådholm K et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.03.027

image credits